TB-500 (10 mg Vial) Protocol

TB-500 is the synthetic peptide corresponding to the active heptapeptide region of thymosin beta-4, most often discussed in the research community for tissue repair and recovery work. This page walks through a 10 mg vial specifically. It covers how the vial is reconstituted, what the math looks like on an insulin syringe, and the titration pattern most commonly referenced when people discuss handling this compound. For the underlying published research (mechanism, study types, citations), see the TB-500 research notes.

Quick reference

Reconstitution and syringe math

For a 10 mg vial, adding 2 mL of bacteriostatic water gives a concentration of 5,000 mcg per mL. That's a clean number to work with on a standard U-100 insulin syringe, where 100 units equals 1 mL.

1. The vial and the bacteriostatic water are usually brought to room temperature first, with both stoppers wiped with an alcohol swab.
2. 2 mL of bacteriostatic water is commonly added slowly, down the inside wall rather than onto the powder, to avoid foaming.
3. The vial is swirled, not shaken, until the powder is fully dissolved and the solution is clear and colorless.
4. Vials are commonly labeled with the concentration and the date of reconstitution.
5. Between draws the vial is kept refrigerated, with a fresh sterile syringe used for each draw.

Worked example: a 500 mcg dose at 5,000 mcg/mL works out to 0.1 mL, which is 10 units on a 100-unit syringe. A 250 mcg dose is half that: 0.05 mL, or 5 units. The full method behind this math (and a calculator you can plug your own numbers into) is on the bac water and syringe math guide.

Titration schedule researchers commonly reference

There's no single official protocol for TB-500. What follows is the general pattern most often referenced in the research community, which is a shorter loading phase followed by a lower-frequency maintenance phase. It is not drawn from a completed human dose-finding trial, since none exists for this compound; treat it as a measurement reference, not instructions to follow.

A single 10 mg vial, reconstituted this way, supplies exactly 20 doses at the 500 mcg mark, roughly half the 36–40 draws the schedule above implies. The number worth carrying into a price comparison isn't a vial count though, it's the total milligrams: the full 8-week schedule works out to roughly 11–20 mg of TB-500, depending on the loading dose and how often the maintenance phase is dosed.

Supplies for a full cycle

• TB-500, total quantity: roughly 11–20 mg across an 8-week window, depending on the loading dose and maintenance frequency chosen. Vials are sold in several sizes, so compare on price per milligram rather than counting vials
• Insulin syringes (U-100, 1 mL): roughly one per draw, so 36–40 for an 8-week window at the schedule above, or closer to 65 if the loading phase is split into two daily doses
• Bacteriostatic water: one 10 mL bottle comfortably covers several reconstitutions
• Alcohol swabs: one 100-count box covers an 8-week window with room to spare

Storage and handling

The sealed lyophilized vial is kept at room temperature or refrigerated, away from light. Once reconstituted it is refrigerated at 2–8°C and used within about 4 weeks, as most commonly referenced by suppliers. Freezing the reconstituted solution is generally avoided, as are repeated freeze-thaw cycles. A new sterile syringe is used for each draw rather than re-entering the vial with a used needle, and site rotation is commonly referenced to limit local irritation.

How TB-500 works

TB-500 corresponds to the active heptapeptide sequence (Ac-LKKTETQ) of thymosin beta-4, a naturally occurring actin-binding protein. It's studied for its role in cell migration, angiogenesis, and tissue repair, largely in preclinical animal and in vitro models, with the most clinically advanced application being ocular surface treatment.[1] The full mechanism and research areas are covered in more depth on the TB-500 research notes page.

What's reported

From published research:

• Cell migration and angiogenesis activity linked to actin-binding, mostly in animal and in vitro models[2]
• Cardiac repair signals in preclinical ischemia models[3]
• Human clinical trial data for the parent molecule, thymosin beta-4, in ocular surface conditions[1]

Commonly reported in the community (not clinical data):

• Generally described as well tolerated at the doses in the table above
• Occasional mild injection-site redness or tenderness
• No completed large-scale human safety trial for TB-500 specifically, so this category of report should be weighted accordingly